Clinical risk factors for portopulmonary hypertension

Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the predictors and biologic mechanism for the development of this complication are unknown. We sought to determine the clinical risk factors for portopulmonary hypertension in patients with advanced liver disea...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 48; no. 1; pp. 196 - 203
Main Authors Kawut, Steven M., Krowka, Michael J., Trotter, James F., Roberts, Kari E., Benza, Raymond L., Badesch, David B., Taichman, Darren B., Horn, Evelyn M., Zacks, Steven, Kaplowitz, Neil, Brown, Robert S., Fallon, Michael B.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2008
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Portopulmonary hypertension affects up to 6% of patients with advanced liver disease, but the predictors and biologic mechanism for the development of this complication are unknown. We sought to determine the clinical risk factors for portopulmonary hypertension in patients with advanced liver disease. We performed a multicenter case‐control study nested within a prospective cohort of patients with portal hypertension recruited from tertiary care centers. Cases had a mean pulmonary artery pressure > 25 mm Hg, pulmonary vascular resistance > 240 dynes · second · cm−5, and pulmonary capillary wedge pressure ≤ 15 mm Hg. Controls had a right ventricular systolic pressure < 40 mm Hg (if estimable) and normal right‐sided cardiac morphology by transthoracic echocardiography. The study sample included 34 cases and 141 controls. Female sex was associated with a higher risk of portopulmonary hypertension than male sex (adjusted odds ratio = 2.90, 95% confidence interval 1.20‐7.01, P = 0.018). Autoimmune hepatitis was associated with an increased risk (adjusted odds ratio = 4.02, 95% confidence interval 1.14‐14.23, P = 0.031), and hepatitis C infection was associated with a decreased risk (adjusted odds ratio = 0.24, 95% confidence interval 0.09‐0.65, P = 0.005) of portopulmonary hypertension. The severity of liver disease was not related to the risk of portopulmonary hypertension. Conclusion: Female sex and autoimmune hepatitis were associated with an increased risk of portopulmonary hypertension, whereas hepatitis C infection was associated with a decreased risk in patients with advanced liver disease. Hormonal and immunologic factors may therefore be integral to the development of portopulmonary hypertension. (HEPATOLOGY 2008.)
Bibliography:Potential conflict of interest: Dr. Taichman received grants from Actelion. Dr. Trotter received grants from Roche, Debivision, and Wyeth. He is on the speakers' bureau of Salix and Astellis. He consults for and received grants from Novartis. Dr. Kawut is a consultant for Encysive. He is a consultant for, advises, is on the speakers' bureau of, and received grants from Gilead. He is on the speakers' bureau of and received grants from Pfizer and Actelion. He is a consultant for and received grants from United Therapeutics. He is on the speakers' bureau of INO Therapeutics. He received grants from Lung Rx. Dr. Badesch is a consultant for, is on the speakers' bureau of, advises, and received grants from GlaxoSmithKline, United Therapeutics/Lung Rx, Actelion/CoTehrix, Encysive, Pfizer, and Gilead/Myogen. He also received grants from Lilly/ICOS. He is a consultant for and advises Mondo‐Biotech and Biogen IDEC.
fax: 212‐342‐5382.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0270-9139
1527-3350
DOI:10.1002/hep.22275